Day 4 Highlights from ASH 2024: Pediatric ALL, Epcoritamab, and a Next-Gen CLL Combo

On Day 4 of ASH 2024, explore the remarkable 96% disease-free survival with Blincyto in pediatric ALL, deep responses with Epcoritamab in relapsed CLL, and the promise of a next-gen BCL2 inhibitor in a potent CLL combination. Tune in for transformative insights! Like what you hear? Download Curie from the App store for personalized insights.